Trump signs order to speed review of psychedelics, including ibogaine
Read Original Source
President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and conservative lawmakers despite having serious safety risks. President Donald Trump holds up a signed executive order in the Oval Office of the White House, Saturday, April 18, 2026, in Washington. (AP Photo/Julia Demaree Nikhinson) President Donald Trump shakes hands with U.S.
AI Summary
Main Idea: President Donald Trump ordered faster federal review of certain psychedelic drugs, including ibogaine, as the Food and Drug Administration and the Department of Health and Human Services move to speed research and possible medical use.
Key Points:
- Trump said the change could help people with severe mental health problems get new treatment options faster.
- The FDA plans to issue priority vouchers that could cut review times from months to weeks for some psychedelic drugs.
- Ibogaine remains illegal and carries serious safety risks, including heart problems, but supporters say it may help with PTSD and opioid addiction.
- The Department of Health and Human Services will direct at least $50 million to state programs that support research on psychedelic drugs.
Impact on the People
Negative Impact
Faster federal review of ibogaine could expose patients to heart risks before safety is fully proven.
Positive Impact
New FDA and HHS support may speed research and could lead to better treatments for PTSD, depression, and addiction.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Food and Drug Administrationgovernment agency or body
- Primary:President Donald Trumpperson
Candidate Entities11 candidates · 5 weighted vote min · 70% decision
- Food and Drug Administrationgovernment agency or bodyPrimaryEvaluated
Central regulator taking concrete action to fast-track review of psychedelics and clear the way for human trials.
Include 0 (0%)Ignore 0 (0%)5 to threshold - President Donald TrumppersonPrimaryEvaluated
Central actor who signed the executive order directing faster review of psychedelics.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Joe RoganpersonMajorAI selected
Public figure whose advocacy and direct appeal to Trump are part of the story’s central action.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Marcus LuttrellpersonMajorAI selected
Named veteran and public supporter who appeared with Trump and endorsed ibogaine.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Marty MakarypersonMajorAI selected
FDA commissioner quoted on the agency’s fast-track voucher plan, a key action in the article.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Secretary of Health and Human Services Robert Kennedy Jr.personMajorAI selected
Named administration official involved in the push to ease access to psychedelics.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Governor Rick PerrypersonContextCandidate
Former governor cited as a backer of ibogaine research and federal relaxation efforts.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment